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Abstract
There is an urgent need for effective prophylactic measures againstMycobacterium tuber-
culosis (Mtb) infection, particularly given the highly variable efficacy of Bacille Calmette-
Guerin (BCG), the only licensed vaccine against tuberculosis (TB). Most studies indicate
that cell-mediated immune responses involving both CD4+ and CD8+ T cells are necessary
for effective immunity againstMtb. Genetic vaccination induces humoral and cellular
immune responses, including CD4+ and CD8+ T-cell responses, against a variety of bacte-
rial, viral, parasitic and tumor antigens, and this strategy may therefore hold promise for the
development of more effective TB vaccines. Novel formulations and delivery strategies to
improve the immunogenicity of DNA-based vaccines have recently been evaluated, and
have shown varying degrees of success. In the present study, we evaluated DNA-launched
Venezuelan equine encephalitis replicons (Vrep) encoding a novel fusion of the mycobacte-
rial antigens α-crystallin (Acr) and antigen 85B (Ag85B), termed Vrep-Acr/Ag85B, for their
immunogenicity and protective efficacy in a murine model of pulmonary TB. Vrep-Acr/
Ag85B generated antigen-specific CD4+ and CD8+ T cell responses that persisted for at
least 10 wk post-immunization. Interestingly, parenterally administered Vrep-Acr/Ag85B
also induced T cell responses in the lung tissues, the primary site of infection, and inhibited
bacterial growth in both the lungs and spleens following aerosol challenge withMtb. DNA-
launched Vrep may, therefore, represent an effective approach to the development of gene-
based vaccines against TB, particularly as components of heterologous prime-boost strate-
gies or as BCG boosters.
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Introduction
A third of the human population is latently infected withMycobacterium tuberculosis (Mtb),
and at risk for disease reactivation [1]. TheWorld Health Organization global TB report for 2014
estimated 9 million new TB cases and 1.5 million TB-related deaths in 2013 [2]. Increases in the
incidence of TB are fueled by infections caused by multi-drug resistant and extensively-drug
resistantMtb strains, while, co-infection with HIV-1 is the most common cause of immune sup-
pression in latently infected individuals, raising the risk of TB disease from a 10% lifetime chance
to 10% annually [3]. AlthoughMycobacterium bovis BCG, the only licensed TB vaccine, is widely
used for routine childhood vaccinations, its variable efficacy in adults and concerns with its use
in HIV-infected persons warrants the development of novel and more effective prophylactic vac-
cines for controlling the TB epidemic [1,4–6]. Immune correlates of vaccine-mediated protection
againstM. tuberculosis infection are not yet well defined, however most studies indicate that T
helper type 1 (Th1) cell-mediated immune responses mediated by CD4+ and CD8+ T cells are
important components of an effective immune response to TB infection [7–10].
DNA vaccination has been used to induce humoral and cellular immunity, including CD4
+ and CD8+ T-cell responses against a variety of bacterial, viral, and parasitic antigens, and
affords some protective immunity against these pathogens [11,12]. However, conventional
DNA vaccines are poorly immunogenic in larger mammals, including primates and humans
[13–16]. DNA vaccines have been clinically tested in vaccine trials against HIV and malaria,
but to date, they have not entered clinical trials as candidate TB vaccines [17–19]. New formu-
lation and delivery strategies to improve their immunogenicity have recently been evaluated,
including the use of “DNA-launched” replicons derived from alphaviruses [20–24]. Alpha-
viruses are arthropod-borne members of the family Togaviridae with a positive-sense single-
stranded RNA genome. Replicons based on different alphaviruses, including Sindbis virus
(SINV), Semliki Forest virus (SFV) and Venezuelan equine encephalitis virus (VEEV), have
recently been developed as a vaccine vector platform [24–31]. Replacement of structural genes
downstream of the internal 26S promoter with a transgene of interest gave rise to virus-repli-
con particles (VRP) expressing high levels of the gene product, while the particles themselves
appear to target dendritic cells [32,33], activate a variety of innate inflammatory factors [34,35]
and induce apoptosis [36,37], all attractive features for vaccination. However, potential safety
issues and problems with large-scale manufacture of alphavirus VRP have hampered their fur-
ther development. The recent development of self-amplifying replicons “launched” from DNA
plasmids addresses these issues, while providing DNA-based vaccines of greatly enhanced
immunogenicity [24–29]. These constructs are essentially DNA vaccines where a cDNA copy
of the viral replicase and the vaccine antigen are placed on a plasmid backbone under the con-
trol of a cytomegalovirus promoter [28]. They retain the immune-stimulatory qualities of VRP
and have proven to be immunogenic in several murine models of infection [24–29].
In the present study, we have engineered DNA-launched VEE replicons (Vrep) encoding a
fusion of two mycobacterial antigens, Ag85B and α-crystallin (Acr). Ag85B is an immunogenic
mycolyl transferase involved in the coupling of mycolic acids with arabinogalactan and is nec-
essary for cell wall formation [38]. Acr is a 16kDa homolog of α-crystallin family of heat shock
proteins and is a part of the 48-gene DosR (regulator of dormancy) regulon under the control of
the transcription factor DosR [39,40]. Acr is widely regarded as a “latency associated antigen”,
but appears to be immunogenic soon after infection in the mouse model (Mehta and Ramsay,
unpublished data). We have evaluated the immunogenicity and protective efficacy of these con-
structs in a mouse model of acute pulmonary TB infection. Our studies indicate that Vrep induce
long-lasting antigen-specific T cell responses in both the spleen and in pulmonary tissues, and
reduce bacterial loads in these tissues following aerosol challenge with virulentMtb.
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Material and Methods
Vaccine vectors
A gene fusion encoding Acr (GenBank Acc No. M76712.1) upstream of Ag85B (GenBank Acc.
No. X62398) was codon-optimized using the Java Codon Optimization Tool (http://www.jcat.
de) and was manufactured by GenScript (Piscataway, New Jersey).
The methodology for construction of pHis DNA vaccines has been described elsewhere
[41]. For construction of pHis-Acr/Ag85B (DNA-Acr/Ag85B), the Acr/Ag85B gene fusion was
PCR-amplified from pUC57-Acr/Ag85B and subcloned into the DNA vaccine vector-pHis
that contains CpG motifs in the vector backbone (Coley Pharmaceutical Group, Wellesley,
Massachusetts) as a BamHI/EcoRI fragment using T4 DNA Ligase (Invitrogen, Carlsbad, Cali-
fornia). The ligation product was transformed into competent TOP10 E. coli cells (Invitrogen)
and positive clones were confirmed by PCR using vector-specific primers and DNA sequenc-
ing. pHis vectors without Acr/Ag85B gene inserts were used as control DNA vaccines. DNA
vaccines were prepared in bulk for in vivo experiments using the Endo-free plasmid Mega kit
(Qiagen, Gaithersburg, Maryland) according to the manufacturer’s instructions, and were
resuspended in 0.85% sterile saline.
The Venezuelan equine encephalitis virus (VEEV) DNA plasmid replicon (pVrep) was con-
structed using overlap PCR to fuse the 5’ end of the Trinidad Donkey strain replicon vector,
pVR21 [42,43] to the estimated RNA transcriptional start sequence of the cytomegalovirus
Immediate Early gene promoter in the pCMV-Tag cloning vector (Agilent Technologies). This
generated an amplicon of 1.37 kb containing the entire 700bp CMV promoter and 670 bp of
the 5’ end of the replicon which was subsequently cloned into the pCR-Blunt vector using the
ZeroBlunt cloning Kit (Agilent Technologies). Using HpaI and NotI, the 3’ end of the pVR21
replicon was then cloned into the pCR-blunt vector, creating the Vrep replicon launched by
the CMV promoter.
The firefly luciferase (Luc), green fluorescent protein (GFP) or Acr/Ag85B genes were
cloned into the pCR-Blunt vector as AscI/PacI fragments using the ZeroBlunt cloning kit and
then transferred into pVrep via Asc I and Pac I sites as previously described [44], giving rise to
Vrep-Luc, Vrep-GFP, and Vrep-Acr/Ag85B respectively. To confirm protein expression, BHK
cells were electroporated with 20 μg of GFP or Acr/Ag85B pVrep using a BioRad electorporator
(200 mV, 1000μF resistance). At 18–24 hrs post electroporation, cells were lysed using whole
cell lysis buffer and 20–30μg separated by SDS-PAGE followed by western blot for FLAG Tag
as previously described [44,45].
Animals
Specific-pathogen-free mice were purchased from Charles River (Raleigh, North Carolina) and
housed in the Louisiana State University Health Sciences Center (LSUHSC) animal care facil-
ity. 6–8 wk old female Balb/c mice were used in all experiments. BCG vaccinated and/orM.
tuberculosis-challenged mice were housed in a Biocontainment Level-3 (BSL-3) Laboratory
operated in accordance with the appropriate safety precautions recommended by the Centers
for Disease Control and Prevention and monitored by the LSUHSC Institutional Biosafety
Committee.
Ethics Statement
All procedures involving mice were approved by the Louisiana State University Health Sciences
Center Institutional Animal Care and Use Committee (IACUC), Approval Number 3010.
LSUHSC Animal Care is fully accredited by AAALAC. All invasive procedures were performed
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under anesthesia with a mixture of KetaThesia (ketamine HCl, 100 mg/mL, Butler Animal
Health Supply, Dublin, Ohio) and xylazine (10 mg/mL, Henry Schein, Mandeville, Louisiana)
diluted eight-fold in phosphate-buffered saline (PBS; Gibco, Invitrogen, Carlsbad, California).
Mice were euthanized by cervical dislocation under anesthesia.
Immunization
Animals were immunized with Vrep or conventional DNA vaccines at the time points indi-
cated in Table 1, with specific details in figure legends. For immunization, 10ug of Vrep or
30ug of conventional pHis DNA vaccine were given by an intramuscular (IM) injection into
each tibialis muscle (20ug Vrep or 60ug total DNA respectively in phosphate-buffered saline
(PBS)) followed by immediate electroporation with 5 pulses at 150 V using an ECM 830 Elec-
troporation System and caliper electrode (BTX–Harvard Apparatus, Holliston, Massachusetts).
These vaccine doses were previously shown, by IFNγ ELISPOT assay, to be optimal in mice for
immune priming of CD4+ T cells for subsequent boosting with recombinant adenovirus vac-
cines encoding homologous vaccine antigens (ref 41, data not shown).
Isolation of mononuclear cells
At 3 or 10 wk post-immunization, animals were euthanized, and spleens were isolated by gross
dissection. Tissues were processed into single-cell suspensions in complete medium (CM) con-
sisting of RPMI 1640 supplemented with 20 mM L-glutamine, 10 mMHEPES, 50 ug/mL strep-
tomycin, 50 U/mL penicillin, 50 mM 2-mercaptoethanol (Sigma–Aldrich, St. Louis, Missouri)
and 10% FCS (Hyclone, Thermo Fisher Scientific, Waltham, Massachusetts). All reagents were
purchased from Gibco unless otherwise specified. Red blood cell lysis was performed using
RBC Lysing Buffer (Sigma–Aldrich). Lung tissues were also harvested, minced in sterile 25ml
beakers, and incubated in complete digestion medium (CDM) in a 37° C water bath prior to
processing into single-cell suspensions as described above. CDM consisted of CM without FCS,
and with addition of 1mg/ml collagenase I and 30ug/ml DNase I (Worthington Biochemical
Corp, Lakewood, NJ).
Peptides
Synthetic peptide oligomers representing CD4+ and CD8+ T cell epitopes in Acr and Ag85B
were used to stimulate antigen-specific responses in IFN-γ ELISpot and intracellular cytokine
staining assays. The peptide sequences were as follows: Acr CD4+ T cell epitope RDGQLTI-
KAERTEQKDFDGRS [46,47], Ag85B CD4+ T cell epitope HSWEYWGAQLNAMKGDLQ
Table 1. Immunization Protocols.
Group Week 0 Week 3 or 6
DNA Vaccination DNA-control DNA-Acr /Ag85B
DNA-Acr/Ag85B DNA-Acr /Ag85B
Vrep immunization Vrep-Luc Vrep-Luc
Vrep-Luc Vrep-Acr/Ag85B
Vrep-Acr/Ag85B Vrep-Acr/Ag85B
DNA vaccines were administered IM as described in Materials and Methods, such that each animal
received a total of 60μg of designated vaccine at week 0 and again at week 3. Vrep vaccines were given
IM as described in Materials and Methods, such that each animal received a total of 20μg of designated
vaccine at week 0 and again at week 3 or week 6. See ﬁgure legends for speciﬁc details within each
experiment.
doi:10.1371/journal.pone.0136635.t001
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[48], Ag85B CD8+ T cell epitope MPVGGQSSF [49], and Acr CD8+ T cell epitope TYDK-
GILTV (Mehta and Ramsay, unpublished). All peptides were synthesized by Genscript (Piscat-
away, NJ).
Interferon gamma (IFN-γ) EliSPOT Assay
IFN-γ ELISpot was performed using 96-well Multiscreen TM-IP plates (Millipore, Billerica,
Massachusetts) and Mabtech reagents for ELISpot assay for mouse interferon-γ (Mariemont,
Ohio) according to manufacturer’s protocols and as described elsewhere [41]. Cells were stim-
ulated with CD4+ or CD8+ peptides at a final concentration of 5 ug/mL. Spots were developed
using BCIP/NBT substrate (Moss Substrates, Pasadena, Maryland) and counted with an
AID-ELISPOT counter (AutoImmun Diagnostika GmbH, Strasburg, Germany). Data are pre-
sented as spot forming cells (SFCs) per million cells.
Intracellular cytokine staining (ICS)
Two million lymphocytes were seeded into 96 well round bottomed plates (Corning Enter-
prises, Corning, New York) and stimulated with 5 ug/mL peptides at 37° C for 2 hours, then
treated with BD GolgiPlug Protein Transport Inhibitor (BD Pharmigen, San Diego, California)
at 0.1 uL/well, followed by incubation at 37° C for an additional 4 hours. Control wells without
peptide restimulation were established within in each experiment. Cells were then stained with
anti-CD3, anti-CD4 and anti-CD8 antibodies, washed, fixed and permeabilized using BD
CytoFix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, San Diego, California), and
then stained for intracellular expression of IFN-γ, TNF-α and IL-2. Fluorochrome antibodies
used for staining included CD3e-Pacific Blue, CD4-FITC, CD8-PE-Cy5, IFN-γ-APC, IL-2-PE,
and TNF-α-PE-Cy7 (BD Pharmigen). 400,000 events were acquired on a BD LSR II flow
cytometer and data were analyzed using FlowJo software version 8.8.6 (Tree Star, Ashland,
Oregon). For analysis, lymphocyte populations were initially identified by forward-scatter
(size) and side-scatter (granularity) profiles. Lymphocytes positive for CD3 were subsequently
sorted into CD3+CD4+ and CD3+CD8+ subsets, prior to the measurement of cytokine secre-
tion. Multifunctional T cell subsets were identified using the Boolean gating feature in FlowJo.
AerosolizedM. tuberculosis challenge
Mtb strain H37Rv (ATCC No. 27294, Rockville, MD) was grown in Middlebrook 7H11 broth
at 37°C for 14 days. The culture was concentrated by centrifugation, gently sonicated at 95 W
for 10 seconds in a cup-horn sonicator, and stored in aliquots at -80°C after titration. At the
time of inoculation, an aliquot was thawed, gently sonicated, and diluted in endotoxin-free PBS
at 2 x 106 colony-forming units (CFU)/ml. For the challenge experiment at 10 wk after their
second immunization with Vrep-Acr/Ag85B or DNA-Acr/Ag85B, mice were givenMtb by the
aerosol route in a Glas-Col inhalation exposure system (Glas-Col, LLC, Terre Haute, IN).
Exposure times were calibrated to deliver 50–100 CFU of bacteria into the lungs of each
infected mouse. Control mice were given 1x105 CFU of BCG, or were mock-immunized with
saline, subcutaneously via the footpad at 3 wk or 10 wk prior toMtb challenge. Mice were sacri-
ficed at 6 wk afterMtb challenge, and bacterial loads in the lungs and spleens were determined
by serial dilution of tissue homogenates on 7H11 agar plates in quadruplicate. The plates were
incubated at 37°C for 21 days in sealed plastic bags prior to counting bacterial colonies.
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Statistical analysis
The unpaired two-tailed Student’s t-test was used to determine statistical significance of all
data. P-values of 0.05 or less were considered significant.
Results
Confirmation of expression of Acr/Ag85B fusion by Vrep
As shown in Fig 1, expression of the Acr/Ag85B fusion by Vrep-Acr/Ag85B was confirmed by
Western blot using a FLAG tag. The band for the fusion protein was seen, as expected, at approx-
imately 55kD. The presence of multiple gel bands is sometimes seen with replicon expression,
since the replicons themselves can affect macromolecular synthesis within transfected cells. The
presence of multiple bands in the ACR/Ag85 lanes could reflect these effects. In addition, due to
a high level of expression from the subgenomic promoter of the replicon, certain forms/com-
plexes of the protein may also be expressed that have previously not been detected.
Vrep encodingMtb fusion antigen generates sustained antigen-specific
T cell responses
Initial experiments were designed to evaluate the immunogenicity of DNA launched Vrep vac-
cines encoding the Acr/Ag85B fusion antigen. Mice immunized with either one or two doses of
Vrep-Acr/Ag85B generated strong CD4+ T and CD8+ T cell responses in the spleen as measured
in IFN-γ ELISPOT assays (Fig 2). Significantly higher numbers of Acr-specific CD4+ and CD8
+ T cells producing IFN-γ were observed following a second dose of Vrep-Acr/Ag85B, while
approximately 2-fold higher numbers of Ag85B-specific CD4+ T cell responses, and far greater
numbers of Ag85B-specific CD8+ T cells were seen after two doses (Fig 2). These data show a
clear boosting effect of Vrep. T cell responses to both of the antigens encoded by the vaccine were
evident after priming and boosting, demonstrating the immunogenicity of the Acr/Ag85B fusion.
Negligible responses were detected following vaccination with conventional DNA vaccine
Fig 1. Expression of Acr/Ag85B fusion protein in Vrep-Acr/Ag85B confirmed byWestern blot. BHK
cells were electroporated with 15μg of plasmid replicons or were not electroporated (mock), lysates were
prepared 18 hours later, and aWestern blot was performed using anti-FLAG antibody as described in
Materials and Methods.
doi:10.1371/journal.pone.0136635.g001
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encoding the fusion antigen, despite the capacity of these constructs to prime for antigen-specific
CD4+ and CD8+T cell responses upon subsequent boosting with recombinant adenovirus vec-
tors that also encoded Acr/Ag85B (data not shown).
In order to measure the longevity of T cell responses induced by the Vrep fusion, mice were
immunized as before, with two doses of vaccine at 3 wk intervals. As shown in Fig 3, in mice
given Vrep-Acr/Ag85B, Acr and Ag85B-specific CD4+ and CD8+ T cell IFN-γ responses seen
in the spleen at 3 wk post boosting persisted for at least 10 wk, indicative of the generation of
sustained T cell responses against both antigens. Negligible responses were seen at 10 wk in
mice given DNA-Acr/Ag85B (data not shown), as had been found at the 3 wk time point. The
reminder of the study was focused on the immunogenicity and protective efficacy of the Vrep-
Acr/Ag85B construct.
Next, intracellular cytokine staining was performed in order to evaluate numbers of poly-
functional CD4+ and CD8+ T cells that were generated in the spleen following immunization
with Vrep-Acr/Ag85B (Fig 4). Consistent with the ELISpot data, Acr-specific (Fig 4B) and
Ag85B-specific (Fig 4C) CD4+ T cell responses were found at both 3 wk and 10 wk post-boost-
ing. Acr-specific and Ag85B-specific CD4+ T cell subsets secreting IFN-γ/TNF-α/IL-2 or IFN-
γ/TNF-α were particularly evident at the later time point, indicative of a persistent, mature T
cell response to Vrep-encoded antigens. Indeed, the relative proportions of responding poly-
functional subsets, and those secreting individual cytokines, by 10 wk after immunization were
similar (in the case of Acr) or increased (Ag85B) compared to the profiles seen at 3 wk post-
immunization, as shown in the pie-charts under Fig 4B and 4C. Significant numbers of IL-2
secreting CD4+ T cells, either polyfunctional or producing IL-2 alone, were also present at 10
wk after boosting. Antigen-specific CD8+ T cell responses following Vrep immunizations
Fig 2. Vrep-Acr/Ag85B is immunogenic for CD4+ and CD8+ T cell responses.Mice were immunized twice at weeks 0 and 3 with Vrep or conventional
DNA vaccines as described in Materials and Methods and shown in Table 1. The different immunization groups are denoted by the initial vaccine given at
week 0 followed by the second vaccine given at week 3 (eg. DNA-control:DNA-Acr/Ag85B). Splenocytes were harvested at 3 wk post-immunization and both
Acr and Ag85B-specific CD4+ (A) and CD8+ (B) T cell responses were assessed by IFN-γ ELISpot assay. Data shown are mean counts of spot forming cells
(SFCs) ± SEM from pooled splenocyte samples (n = 5) in a single experiment and are representative of three such experiments, * p < 0.05, + p < 0.01, by
Students t-test.
doi:10.1371/journal.pone.0136635.g002
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showed a similar profile to their CD4+ T cell counterparts (data not shown). Ag85B or Acr-
specific T cell responses were negligible in mice primed with control Vrep-Luc or among cells
cultured in the absence of Ag85B or Acr peptides (data not shown).
Systemic and mucosal immune responses to parenteral Vrep-Acr/
Ag85B delivery were not enhanced by extension of the interval between
immunizations
In attempts to optimize the outcome of Vrep immunization, we investigated whether increas-
ing the interval between successive doses of Vrep-Acr/Ag85B from 3 wk to 6 wk affected vac-
cine immunogenicity. Ten wk after the last dose of Vrep in each case, mice were sacrificed to
assess antigen-specific CD4+ and CD8+ T cell responses by IFN-γ-ELISpot (Fig 5). The magni-
tude of Acr-specific CD4+ (Fig 5A) and CD8+ (Fig 5B) T cell responses measured in spleno-
cytes was not significantly affected by increasing the interval to 6 wk, while corresponding
Ag85B-specific T cell responses were actually diminished. The opportunity was also taken in
this experiment to study vaccine-specific T cell responses in the lungs of mice given Vrep via
the i.m. route, the rationale being that local immune responses againstMtb are potentially
important, given the usual pulmonary route of infection. Interestingly, antigen-specific CD4+
(Fig 5A) and CD8+ (Fig 5B) T cell responses against both Acr and Ag85B components of the
vaccine were found in the lungs of systemically immunized mice. Indeed, pulmonary responses
were of greater magnitude than corresponding splenic responses in these animals, particularly
in the case of CD4+ T cell immunity. It was also clear that increasing the interval between i.m.
doses of Vrep from 3 wk to 6 wk diminished vaccine-induced pulmonary CD4+ and CD8+ T
cell responses. Further analyses of the numbers of Acr and Ag85B-specific multifunctional
Fig 3. CD4+ and CD8+ T cell IFN-γ responses induced by Vrep vaccination persist at least up to 10 weeks post immunization.Mice were immunized
twice at weeks 0 and 3 with Vrep-Luc or Vrep-Acr/Ag85B vaccines as described in Materials and Methods and shown in Table 1. Splenocytes were
harvested at 3 or 10 weeks post immunization and Acr and Ag85B-specific CD4+ (A) and CD8+ (B) T cell responses were assessed by IFN-γ ELISpot. Data
shown are mean counts of spot forming cells (SFCs) ± SEM from pooled splenocyte samples (n = 5) in a single experiment and are representative of three
such experiments. Student’s t-test was used for all group comparisons.
doi:10.1371/journal.pone.0136635.g003
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CD4+ and CD8+ T cells secreting IFN-γ, TNF-α and IL-2 in lungs and spleens, by intracellular
cytokine staining, confirmed these findings (data not shown).
In summary, it was evident that i.m. delivery of Vrep encoding Acr/Ag85B generated strong
systemic and pulmonary mucosal CD4+ and CD8+ T cell responses. The development of sig-
nificant levels of Th1-type T cell immunity in the lung tissues following systemic administra-
tion of these constructs is of interest, given the primary route of infection byMtb. It was also
clear that increasing the interval between doses of Vrep was of no apparent benefit in terms of
the magnitude of resulting systemic or local T cell responses.
Immunization with Vrep-Acr/Ag85B vaccine protects mice against
pulmonary challenge with aerosolizedM. tuberculosis
Given the strong systemic and pulmonary mucosal CD4+ and CD8+ T cell responses generated
after i.m. delivery of Vrep, we used a mouse model of pulmonaryMtb infection to evaluate the
Fig 4. Multifunctional CD4+ T cells persist for at least 10 weeks post immunization with Vreps.Mice were immunized twice at weeks 0 and 3 with Vrep-
Luc or Vrep-Acr/Ag85B vaccines as described in Materials and Methods and shown in Table 1. A) Representative dot plots showing lymphocytes gated as
CD3+ CD4+ T cells secreting IFN-γ, TNF-α or IL-2 in response to recall antigen. After gating, Boolean analyses allow determination of concurrent expression
of these cytokines. Splenocytes were harvested at either 3 or 10 weeks post-immunization and Acr-specific (B) and Ag85B-specific (C) CD4+ T cells
producing IFN-γ, TNF-α and/or IL-2 were assessed by ICS after subtraction of values for media controls in each case. Data shown are numbers of cytokine
secreting CD4+ T cells per million CD4+ T cells in splenocytes from individual mice (n = 5) as mean ± SEM in a single experiment that is representative of
three such experiments. * p < 0.05, + p < 0.01, ++ p < 0.001 by Student’s t-test. Pie charts under the bar graphs depict relative percentages of CD4+ T cells in
each vaccine group that produced all three of these cytokines (3+), two of these cytokines (2+) or a single cytokine (1+), after exposure to recall antigen and
were created using the SPICEv4.1.5 and PESTLEv1.5.2 software programs (a gift fromM. Roederer, Vaccine Research Center, NIAID/National Institutes of
Health).
doi:10.1371/journal.pone.0136635.g004
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protective efficacy of Vrep-Acr/Ag85B against an aerosol challenge, since Th1-type immune
responses are thought to be an important component of protection againstMtb infection. Mice
were immunized twice with Vrep-Acr/Ag85B at 3 wk intervals and challenged withM. tubercu-
losisH37Rv strain 10 wk later. Vehicle (naïve) and BCG-vaccinated mice served as negative
and positive control groups respectively. Bacterial loads were enumerated at 6 wk post
challenge.
As shown in Fig 6, vaccination with Vrep-Acr/Ag85B significantly reduced bacterial loads
in the lungs, the primary site of TB infection (Fig 6A), with reductions of the order of 4-fold
compared to ‘naïve’ mice given vehicle only or to mice given control Vrep encoding an irrele-
vant vaccine protein (Vrep-Luc). SinceMtb can disseminate to extra-pulmonary tissues follow-
ing infection, splenic mycobacterial burdens were also quantified to determine the capacity of
Vrep immunization to limit systemic growth. Interestingly, Vrep-Acr/Ag85B significantly
reduced extra-pulmonary growth of mycobacteria, with burdens in the spleens 5-fold lower
than in naïve mice and 4-fold lower than in those given control Vrep. No reductions in bacte-
rial growth were seen in mice immunized with conventional DNA vaccine encoding the Acr/
Ag85B fusion antigen (data not shown). Control mice given BCG at either 3 wk or 10 wk (not
shown) prior toMtb challenge were protected at similar levels.
In conclusion, our data show that immunization with Vrep constructs encoding Ag85B and
Acr via the intramuscular route induced potent antigen-specific CD4+ and CD8+ T cell
responses in both lungs and spleens. Pulmonary mucosal T cell responses correlated with a 4-
5-fold reduction ofMtb growth in immunized mice.
Discussion
In the present study, we evaluated the immunogenicity and protective efficacy of DNA-
launched VEE replicons encoding a novel fusion of the mycobacterial antigens Acr and Ag85B
Fig 5. Increasing the time interval between homologous Vrep-DNA immunizations does not increase the magnitude of T cell IFN-γ responses in
spleens and lungs.Mice were immunized twice at 3 or 6-week intervals with Vrep vaccines and splenocytes and lung lymphocytes were harvested at 10
weeks after immunization for assay of splenic and pulmonary Acr and Ag85B-specific CD4+ T (A) and CD8+ T (B) cell responses by IFN-γ ELISpot, as
described in Materials and Methods and shown in Table 1. Data shown are SFCs/million lymphocytes from pooled splenocytes or lung samples (n = 5) in one
experiment that is representative of three such experiments and are shown as mean SFCs ± SEM. * p 0.05. + p 0.01. ++ p = 0.001 by Student’s t-test.
doi:10.1371/journal.pone.0136635.g005
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in a murine model of pulmonary TB infection. The Vrep-Acr/Ag85B construct was highly
immunogenic, with CD4+ and CD8+ T cell responses against both fusion antigens persisting
for at least 10 wk following immunization. Strikingly, when given intramuscularly, Vrep vac-
cines also generated strong, persistent T cell responses in the pulmonary tissues. This is the
first report of which we are aware showing high-level pulmonary CD4+ and CD8+ T cell
immunity to encoded vaccine antigens following parenteral administration of alphavirus repli-
cons. Vaccine-induced immunity correlated with a 4 to 5-fold reduction in bacterial loads in
pulmonary and extra-pulmonary tissues following aerosol challenge with aerosolizedMtb.
Parenteral delivery of immunogens often fails to induce mucosal immune responses
[50,51]. The capacity of Vrep to induce vaccine-specific T cell responses, including multifunc-
tional T cell responses, in lung tissues of mice immunized up to 10 wk earlier is a potentially
important feature for their further development as a vaccine platform. Multifunctional T cells
secreting IFN-γ and IL-2 are thought to correlate with protective efficacy in several disease
models, including Leishmania major infection in mice [52] and SIV infection in rhesus
macaques [53], while their presence in the lungs correlated with protection in a murine model
of TB infection [54]. In addition, the absence of polyfunctional CD4+ T cells in the lungs of
HIV-infected individuals correlated with a high level of susceptibility to TB infection [55].
While clarification of the protective role of T cell subsets in human TB infection will require
further analyses, including longitudinal studies [56,57], the generation of pulmonary immune
responses against vaccine-expressed TB antigens by Vrep in the present study is of particular
interest, given the primary route of transmission of TB as an aerosol via the lungs, and increas-
ing evidence that local immune defense mechanisms can play an important role in protective
Fig 6. Vrep-Acr/Ag85B vaccine is protective in a murine model of acuteM. tuberculosis infection.Mice were immunized twice with Vrep-Luc or Vrep-
Acr/Ag85B at a 3-week interval as described in Materials and Methods and shown in Table 1. BCG and vehicle immunized mice served as positive and
negative control groups respectively. Ten weeks after immunization, mice (n = 5) were infected via the pulmonary route with 50–100 CFU of aerosolizedMtb
and were sacrificed 6 weeks later for assessment of bacterial burden in lungs (A) and spleens (B). Bacterial colonies were counted at 21 days after plating
lung or spleen homogenates on 7H11 agar plates. Horizontal lines represent mean CFU for each group. For (A) + p < 0.01 (vs Vrep-Luc), ++ p < 0.001 (vs
naïve); for (B) + p < 0.01 (vs Vrep-Luc and vehicle) by Student’s t-test.
doi:10.1371/journal.pone.0136635.g006
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immunity against TB [58]. Induction of effective local and circulating immunity against TB
would help control bacterial numbers in the lungs, while also preventing or reducing extra-pul-
monary growth.
It will be important to clarify mechanisms underlying the induction of pulmonary T cell
responses by Vrep in this system. It appears that VRP themselves can act as adjuvants for both
systemic and mucosal immune responses when given parenterally [30,31], with up regulation
of expression of the mucosal homing receptor α4β7 on antigen-specific T cells in peripheral
draining lymph nodes correlating with increased numbers of these cells in the mucosal tissues
[31]. Further studies will be required to ascertain a role for α4β7, or other mucosal homing cell
surface integrins such as VLA-4, in the mucosal immunogenicity of the DNA-based Vrep
vaccine.
Previous studies using DNA-based Sindbis virus replicons encoding Ag85A [26] or Ag85B
[27] also showed some protective efficacy againstMtb, albeit when challenged at only 4 wk
after parenteral vaccination, while mucosal immunogenicity of these replicons was not
reported. T cell responses generated following parenteral administration of Vrep-Acr/Ag85B
in the present study correlated with 4–5 fold reductions in bacterial loads in the lungs and
spleens of mice following challenge with aerosolizedMtb, compared to those given control
Vrep vaccine. Since challenge occurred at 10 wk post immunization, this represents durable,
albeit relatively modest protection, that was not seen in mice vaccinated with conventional
DNA vaccines encoding the same antigen fusion.
These findings, together with clear indications of their mucosal immunogenicity, suggest
that Vrep are suitable for further testing, particularly as components of heterologous prime-
boost vaccine strategies [59,60]. Parenteral immunization with Vrep encoding immunogenic
Mtb antigens could be used to prime for potent immune responses, both in the spleen and in
pulmonary tissues, that could be greatly enhanced by boosting with viral vectors, particularly
via the respiratory tract. It is also likely that activation of innate and adaptive immune
responses, including memory T cell responses at a local level, would best be achieved by prim-
ing directly via the respiratory route. We have begun studies to test the efficacy of nanoparti-
cle-mediated pulmonary delivery of Vrep in animal models of TB infection, including direct
comparisons of the Vrep-Acr/Ag85B fusion vaccine with Vrep expressing either of these anti-
gens individually. Given the widespread use of the BCG vaccine, heterologous boosting of
BCG-primed immunity will also likely be a key component of future TB vaccine strategies
[60,61]. The lack of efficacy of a parenteral recombinant viral vaccine encoding Ag85A in
BCG-immunized infants in a recent phase IIB trial has highlighted the need for greater under-
standing of the nature of protective immune responses againstMtb infection [62], including
the role of local pulmonary immunity. A number of animal studies have demonstrated
improved protection over BCG vaccine following mucosal rather than parenteral boosting
[54,63,64], or when both BCG and a viral vector boost were given intranasally [65]. The muco-
sal immunogenicity of Vrep suggests that they may also be worthy of testing for their efficacy
as boosters of BCG-primed pulmonary immunity.
Antigen-specific T cell responses to recall antigen are influenced by the maturation state of
responding T cell subsets [66,67]. Varying the time interval between doses of vaccine, such as
in prime–boost immunization, may help to determine whether the kinetics of T cell differentia-
tion influence the immunogenicity and protective efficacy of immunization protocols. Thus,
the interval between doses may be important for induction and possibly maturation of anti-
gen-specific T cells, which could ultimately lead to improved vaccine efficacy. It was clear how-
ever, that extending the interval between Vrep immunizations from 3 to 6 wk in the present
study enhanced neither the magnitude nor quality of T cell responses that were generated.
Based on heterologous prime-boost studies [66,67], increasing the time interval even further
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than 6 wk could enhance vaccine immunogenicity, perhaps via optimizing stimulation of
memory T cells generated following immune priming, although this was not the case in the
present homologous vaccine delivery system. Given their immunogenicity however, it will be
of interest to evaluate Vrep as priming vehicles in a variety of different prime-boost protocols,
where the interval between Vrep priming and the administration of a heterologous booster vac-
cine may be an important determinant of efficacy.
The Acr/Ag85B fusion developed in these studies combines two immunogenicMtb proteins
in a single construct. Acr is widely regarded as a “latency” antigen and is certainly expressed at
high levels during the non-replicating persistence phase ofMtb infection [39,68,69]. Recent
work in this laboratory suggests that Acr, like Ag85B, is immunogenic soon afterMtb infection
in the mouse model, and may therefore also represent a promising target for vaccination
(Mehta and Ramsay, unpublished). Use of the Acr/Ag85B fusion may also hold promise as a
component of a multi-stage gene-based vaccine, capable of eliciting immune responses against
both acute and latent phases of TB infection. This concept was recently tested using a recombi-
nant protein-based subunit fusion vaccine, comprising Ag85B and ESAT6 together with the
TB latency antigen Rv2660c, that mediated significant protective efficacy againstMtb challenge
in mice, when given either pre- or post-TB exposure [70].
In conclusion, our data suggest that Vrep encoding immunogenicMtb proteins can induce
long-lasting, antigen-specific T cell responses both in the spleen and in pulmonary tissues.
These responses correlated with significant reduction of bacterial loads in these tissues follow-
ing pulmonary challenge withMtb. Studies are now underway in our laboratory to evaluate the
mucosal and systemic immunogenicity and protective efficacy of Vrep, when incorporated as a
priming vaccine in heterologous prime-boost immunization protocols, and also as a direct pul-
monary immunogen.
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